Chithranjan Nath, MD
Endocrinology, Diabetes & Metabolism · Fishkill, NYNPI 1053456855
Payments from drug & device makers
Across 513 payments — averaging $339.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$46K
- Sanofi-aventis U.S. LLC$42K
- Novo Nordisk$42K
- AbbVie$35K
- Merck$3K
- IBSA Pharma Inc.$1K
- plus $5K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 84 | $45,621 |
| Sanofi-aventis U.S. LLC | 58 | $42,321 |
| Novo Nordisk | 97 | $41,852 |
| AbbVie | 77 | $35,360 |
| Merck | 12 | $3,349 |
| IBSA Pharma Inc. | 5 | $1,058 |
| Roche Diabetes Care, Inc. | 1 | $777 |
| Boehringer Ingelheim | 31 | $599 |
| Amneal Pharmaceuticals LLC | 26 | $419 |
| Sentynl Therapeutics, Inc. | 1 | $400 |
| Lilly USA, LLC | 21 | $385 |
| Abbott | 17 | $295 |
| Corcept Therapeutics | 11 | $294 |
| Amarin Pharma, Inc. | 14 | $231 |
| Radius Health, Inc. | 9 | $173 |
| Ascendis Pharma Endocrinology Inc | 5 | $139 |
| Bayer | 6 | $135 |
| Medtronic(2 entities) | 6 | $133 |
| Amgen(2 entities) | 5 | $125 |
| Novartis | 3 | $96 |
| Johnson & Johnson(2 entities) | 3 | $83 |
| Madrigal Pharmaceuticals | 2 | $64 |
| Insulet Corporation | 4 | $58 |
| Tandem Diabetes Care, Inc. | 2 | $57 |
| Dexcom, Inc. | 2 | $55 |
| Recordati_rare_diseases_inc. | 3 | $48 |
| Antares Pharma, Inc. | 2 | $34 |
| BETA Bionics, Inc. | 1 | $31 |
| UCB, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
How this compares
$174,309 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Fishkill
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.